Literature DB >> 21907762

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

L A Raymond1, V M André, C Cepeda, C M Gladding, A J Milnerwood, M S Levine.   

Abstract

Huntington's disease (HD) is a progressive, fatal neurological condition caused by an expansion of CAG (glutamine) repeats in the coding region of the Huntington gene. To date, there is no cure but great strides have been made to understand pathophysiological mechanisms. In particular, genetic animal models of HD have been instrumental in elucidating the progression of behavioral and physiological alterations, which had not been possible using classic neurotoxin models. Our groups have pioneered the use of transgenic HD mice to examine the excitotoxicity hypothesis of striatal neuronal dysfunction and degeneration, as well as alterations in excitation and inhibition in striatum and cerebral cortex. In this review, we focus on synaptic and receptor alterations of striatal medium-sized spiny (MSNs) and cortical pyramidal neurons in genetic HD mouse models. We demonstrate a complex series of alterations that are region-specific and time-dependent. In particular, many changes are bidirectional depending on the degree of disease progression, that is, early vs. late, and also on the region examined. Early synaptic dysfunction is manifested by dysregulated glutamate release in striatum followed by progressive disconnection between cortex and striatum. The differential effects of altered glutamate release on MSNs originating the direct and indirect pathways is also elucidated, with the unexpected finding that cells of the direct striatal pathway are involved early in the course of the disease. In addition, we review evidence for early N-methyl-D-aspartate receptor (NMDAR) dysfunction leading to enhanced sensitivity of extrasynaptic receptors and a critical role of GluN2B subunits. Some of the alterations in late HD could be compensatory mechanisms designed to cope with early synaptic and receptor dysfunctions. The main findings indicate that HD treatments need to be designed according to the stage of disease progression and should consider regional differences.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907762      PMCID: PMC3221774          DOI: 10.1016/j.neuroscience.2011.08.052

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  293 in total

1.  Chorea Huntington: a rare case with childhood onset.

Authors:  M Gencik; C Hammans; H Strehl; N Wagner; J T Epplen
Journal:  Neuropediatrics       Date:  2002-04       Impact factor: 1.947

2.  Huntington's disease progression. PET and clinical observations.

Authors:  T C Andrews; R A Weeks; N Turjanski; R N Gunn; L H Watkins; B Sahakian; J R Hodges; A E Rosser; N W Wood; D J Brooks
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

Review 3.  Excitotoxic injury of the neostriatum: a model for Huntington's disease.

Authors:  M DiFiglia
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

4.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

5.  Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease.

Authors:  V W S Kung; R Hassam; A J Morton; S Jones
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

6.  NMDA-stimulated expression of BDNF mRNA in cultured cerebellar granule neurones.

Authors:  M Favaron; R M Manev; J M Rimland; P Candeo; M Beccaro; H Manev
Journal:  Neuroreport       Date:  1993-09-03       Impact factor: 1.837

7.  Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain.

Authors:  J D Wood; J C MacMillan; P S Harper; P R Lowenstein; A L Jones
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

8.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

9.  Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems.

Authors:  Hai-Yan Wu; Fu-Chun Hsu; Amy J Gleichman; Isabelle Baconguis; Douglas A Coulter; David R Lynch
Journal:  J Biol Chem       Date:  2007-05-25       Impact factor: 5.157

10.  Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum.

Authors:  Emily L Jocoy; Véronique M André; Damian M Cummings; Shilpa P Rao; Nanping Wu; Amy J Ramsey; Marc G Caron; Carlos Cepeda; Michael S Levine
Journal:  Front Syst Neurosci       Date:  2011-05-11
View more
  121 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

Review 2.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

Review 3.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

4.  Huntington's disease: easing the NMDAR traffic jam.

Authors:  Anthony Daggett; X William Yang
Journal:  Nat Med       Date:  2013-08       Impact factor: 53.440

Review 5.  Hyperkinetic disorders and loss of synaptic downscaling.

Authors:  Paolo Calabresi; Antonio Pisani; John Rothwell; Veronica Ghiglieri; Josè A Obeso; Barbara Picconi
Journal:  Nat Neurosci       Date:  2016-06-28       Impact factor: 24.884

Review 6.  Toward sophisticated basal ganglia neuromodulation: Review on basal ganglia deep brain stimulation.

Authors:  Claudio Da Cunha; Suelen L Boschen; Alexander Gómez-A; Erika K Ross; William S J Gibson; Hoon-Ki Min; Kendall H Lee; Charles D Blaha
Journal:  Neurosci Biobehav Rev       Date:  2015-02-12       Impact factor: 8.989

7.  C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons.

Authors:  Wangchao Xu; Jin Xu
Journal:  J Neurosci       Date:  2018-07-23       Impact factor: 6.167

Review 8.  Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12.

Authors:  Paula Morales; Israa Isawi; Patricia H Reggio
Journal:  Drug Metab Rev       Date:  2018-02-01       Impact factor: 4.518

9.  Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease.

Authors:  Junmei Wan; Jeffrey N Savas; Amy F Roth; Shaun S Sanders; Roshni R Singaraja; Michael R Hayden; John R Yates; Nicholas G Davis
Journal:  Chem Biol       Date:  2013-11-07

10.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.